The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

Hidetoshi Hayashi(Kindai University), Kazuto Nishio(Kindai University Sakai Hospital), Kazumasa Matsumoto(Osaka Research Institute of Industrial Science and Technology), Yosuke Togashi(Okayama University), Hiroaki Kato(Kyoto University), Marco A. De Velasco(Sakai Municipal Hospital), Isamu Okamoto(Kyushu University Hospital), Akihiko Ito(Kobe University), Hideharu Kimura(Kindai University), Yasuhide Yamada(National Center for Global Health and Medicine), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Tokuzo Arao(Kindai University), Kaoru Tanaka(Kindai University), Yoshihiko Fujita(Kyoto University)
Oncogene
December 23, 2013
10.1038/onc.2013.547
Cited by 143

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
|JAMA Oncology|2017|1k